

PERSONAL INFORMATION

Loredana Militello

Sex Female

Nationality Italian

PREFERRED JOB

Medical oncology

WORK EXPERIENCE

- 16/05/2012 Contract employee
- 02/04/2012 – 15/05/2012 Volunteer doctor
- 21/08/2010 – 23/03/2012 Medical doctor (oncology resident)
Breast and gynecologic cancer, gastrointestinal cancer, sarcomas.
- 28/03/2010 – 17/08/2010 Medical Research
Skin cancer (melanoma) basic scientific research
- 10/12/2008 – 17/03/2010 Post doctorate medical research
Basic scientific research on cancer- Non Hodgkin's Lymphoma, Melanoma
- 28/03/2008 – 03/12/2008 Oncology resident
Basic reaserch in breast cancer

EDUCATION AND TRAINING

24/09/2000 – 26/07/2007 Medical Doctor

Level 6—SECOND
STAGE OF
TERTIARY
EDUCATION

University of Catania,
Medicine and Surgery

22/03/2008 – 23/03/2012 Medical Oncologist
University Of Catania,
Brest and gynecologic cancer, GI cancer, sarcomas

PERSONAL SKILLS

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2
French	B1	B1	A2	A2	B1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2: Proficient user
Common European Framework of Reference for Languages

Communication skills	<ul style="list-style-type: none"> - Good communication skills - Adaptable to multicultural work team, - Socially oriented and easy to work with - Have experience working in different countries
Organisational / managerial skills	<ul style="list-style-type: none"> - Part of the organization team for granting honorary degree in medicine to Margaret Foti, the chief of American Association of Cancer Research in University of Catania. - Part of the collaboration team between Univeristy of Catania and UCLA
Job-related skills	<ul style="list-style-type: none"> - Laboratory skills including cell culture, various assays. - Operate Ultrasound on patients - Paracentesis and thoracentesis on cancer patients
Computer skills	<ul style="list-style-type: none"> - Good command of G2 program for creating database of cancer patients and treatment options. - Good command of Microsoft Office Tools (Word, Excel, Power Point) - Good command of Pubmed
Driving licence	B

ADDITIONAL INFORMATION

1. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF- κ B/Snail/RKIP/PTEN resistance loop in B-NHL cells: Role in sensitization to TRAIL apoptosis. Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B. *Int J Oncol*. 2011 Mar 23. doi: 10.3892/ijo.2011.984.
2. Understanding rituximab function and resistance: implications for tailored therapy. Amoroso A, Hafsi S, Militello L, Russo AE, Soua Z, Mazzarino MC, Stivala F, Libra M. *Front Biosci*. 2011 Jan 1;16:770-82.
3. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF- κ B/Snail/RKIP/PTEN Circuit. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. *Genes Cancer*. 2010 May;1(5):409-420.
4. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. *Cell Cycle*. 2009 May 1;8(9):1367-72. Epub 2009 May 26. Review.
5. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. *Cell Cycle*. 2009 May 1;8(9):1352-8. Epub 2009 May 23. Review.
6. Breast cancer: Molecular basis and therapeutic strategies (Review). Ligresti G, Libra M, Militello L, Clementi S, Donia M, Imbesi R, Malaponte G, Cappellani A, McCubrey JA, Stivala F. *Mol Med Report*. 2008 Jul-Aug;1(4):451-8.
7. IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Malaponte G, Polesel J, Candido S, Sambataro D, Bevelacqua V, Anzaldi M, Vella N, Fiore V, Militello L, Mazzarino MC, Libra M, Signorelli SS. *Cytokine*. 2013 Apr;62(1):64-9. doi: 10.1016/j.cyto.2013.02.017. Epub 2013 Mar 11. PMID: 23490413 [PubMed - in process]
8. Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. Tuzi A, Lombardi D, Crivellari D, Militello L, Perin T, La Grassa M, Massarut S, Veronesi A. *Radiol Oncol*. 2013 Mar;47(1):57-62. doi: 10.2478/raon-2013-0012. Epub 2013 Feb 1. PMID: 23450278 [PubMed]

- Publications 9. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.
Crivellari D, Spazzapan S, Lombardi D, Militello L, Torrasi E, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A.
Tumori. 2012 Jan-Feb;98(1):33-8. doi: 10.1700/1053.11497.

AUIANO 29/06/2013